Livonia, Michigan, Aug. 24, 2023 – a provider of digital therapeutics for insulin management, Hygieia, has announced the hire of Zoe Heineman as Vice President of Business Development.
Heineman brings over 30 years of expertise in strategic leadership, operations, and business development in the biopharmaceutical and medical device industries. She is an internationally known member of the diabetes community with a track record of opening new markets for diabetes technology.
“We are beyond excited to announce that Zoe has joined our management team. She is a champion for better access to effective diabetes care and has a demonstrated history of this in both her professional and personal life,” commented Eran Bashan, Ph.D., Hygieia co-founder and CEO.
From Heineman, “It is inspiring to join the d-Nav team that is building a reality where people who inject insulin have the same freedom of a personalized, closed-loop system, with the added benefit of a diabetes specialist available to them.”
While attending graduate school, Heineman was diagnosed with type 1 diabetes. That diagnosis inspired her to focus her career on improving access to care.
Noted for having led the coalition responsible for adding coverage of insulin pump therapy and disposable supplies cost to Medicare, she also was a start-up team member at Disetronic, an insulin delivery device manufacturer later acquired by Roche for $1.3 billion, a co-chair of the American Association of Clinical Endocrinology Corporate Advisory Board, and a board member of the Lawson Wilkins Pediatric Endocrinology Society.
Heineman is graduate of the School of Foreign Service at Georgetown University, with an MS in Education from Johns Hopkins. She received an Executive MBA in Pharmaceutical Marketing from Rutgers.
Hygieia is the developer of d-Nav®, the first FDA-cleared technology to autonomously adjust insulin doses directly to the patient. d-Nav’s AI-powered technology automatically interprets data and independently initiates insulin management. The d-Nav Insulin Management Program adds clinical support that helps people with type 2 diabetes adjust their insulin doses according to their body’s changing insulin needs. Studies have shown that nearly 90 percent of people using d-Nav report lower A1C in just three months*, without increasing the risk for hypoglycemia*. The d-Nav Insulin Management Program has been peer-reviewed with studies published in leading medical journals. Hygieia is headquartered in Livonia, Michigan. Learn more at d-Nav.com.
* Richard M Bergenstal et al. Automated insulin dosing guidance to optimise insulin management in patients with type 2 diabetes: a multicentre, randomised controlled trial. Lancet 2019 Mar 16;393(10176):1138-1148. https://pubmed.ncbi.nlm.nih.gov/30808512/
Debbie Reinheimer, firstname.lastname@example.org